OptiNose AS Files Investigational New Drug Application to use Sumatriptan Delivered with its Novel Drug Delivery Technology

YARDLEY, Pa.--(BUSINESS WIRE)--OptiNose Inc. announces the filing of an Investigational New Drug (IND) with the U.S. Food and Drug Administration (FDA) in December, 2011. The FDA has completed its review and has notified OptiNose that the studies under this IND may proceed. The Company will initiate Phase III trials in adults with acute migraine with or without aura utilizing its novel intranasal technology.